FDA rejects Daiichi Sankyo's application for pain medication

The FDA declared the application for CL-108, as it stands, not approved.
The FDA declared the application for CL-108, as it stands, not approved. | File photo
The U.S. Food and Drug Administration issued a complete response letter in response to Daiichi Sankyo's new drug application regarding CL-108, a drug used in treating and managing pain.
The FDA declared the application, as it stands, not approved and is providing guidance on information needed to resolve the issues.
Based in New Jersey, Daiichi Sankyo is a pharmaceutical manufacture working to address unmet health care needs.